20.68k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
|Watchlist||Change Today||1 Month Return||1 Year Return||Total Return|
|The Fight Against COVID19||+0.43%||-||-||-|
|Symbol||Company Name||Last Price||Change||% Change||Market Time||Volume||Avg Vol (3 month)||Market Cap|
|JNJ||Johnson & Johnson||165.685||-0.79||-0.48%||10:20 a.m. EDT||1.60M||8.31M||436.20B|
|PFE||Pfizer Inc.||39.452||+0.42||+1.08%||10:20 a.m. EDT||6.98M||31.74M||220.07B|
|ABBV||AbbVie Inc.||111.0767||+2.05||+1.88%||10:20 a.m. EDT||1.48M||7.27M||196.03B|
|SNY||Sanofi||52.45||+0.45||+0.87%||10:18 a.m. EDT||133.38k||2.26M||130.53B|
|GSK||GlaxoSmithKline plc||38.14||+0.44||+1.17%||10:20 a.m. EDT||1.05M||6.43M||93.41B|
|GILD||Gilead Sciences, Inc.||66.63||+0.25||+0.38%||10:20 a.m. EDT||1.09M||7.83M||83.89B|
|MRNA||Moderna, Inc.||160.4311||+3.65||+2.33%||10:20 a.m. EDT||1.86M||10.88M||64.26B|
|REGN||Regeneron Pharmaceuticals, Inc.||509.5||+5.08||+1.01%||10:20 a.m. EDT||143.55k||1.01M||54.58B|
|TAK||Takeda Pharmaceutical Company Limited||16.8616||+0.02||+0.13%||10:19 a.m. EDT||477.19k||3.90M||53.64B|
|BNTX||BioNTech SE||153.5||-2.68||-1.72%||10:20 a.m. EDT||430.63k||1.92M||37.07B|
|NVAX||Novavax, Inc.||210.43||+2.28||+1.10%||10:20 a.m. EDT||832.57k||4.32M||15.54B|
|VIR||Vir Biotechnology, Inc.||46.6573||-1.80||-3.72%||10:19 a.m. EDT||363.86k||1.79M||6.05B|
|INO||Inovio Pharmaceuticals, Inc.||8.77||+0.14||+1.62%||10:20 a.m. EDT||1.14M||15.16M||1.83B|
Assistant Professor of Medicine & Infectious Diseases at University of Nebraska Medical Center, Dr. Jasmine Marcelin, joined Yahoo Finance Live to break down how the JNJ vaccine may return Friday with new limits and what this means for the U.S.
Yahoo Finance's Adam Shapiro caught up with Johnson & Johnson CFO Joe Wolk to discuss JNJ's earnings, vaccine concerns and what the future holds for the pharmeceutical company.
The U.S. Food and Drug Administration (FDA) said it had completed its inspection of a U.S. plant that makes Johnson & Johnson's COVID-19 vaccine and asked for remediation of issues including peeling paint and loose debris at the site. Emergent Biosolutions, which owns the plant, earlier this week said it would stop production of new drug material at the plant, while the FDA conducted an inspection of the facility. The FDA's inspection closeout report, also known as "FDA Form 483", cited observations including failure to train personnel to avoid cross contamination of COVID-19 vaccines from Johnson & Johnson and AstraZeneca.